Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT

Rexhep Durmo 1,2,* , Angelina Filice 1 , Federica Fioroni 3 , Veronica Cervati 4 , Domenico Finocchiaro 3,15, Chiara Coruzzi 1, Giulia Besutti 5 , Silvia Fanello 6, Andrea Frasoldati 7 and Annibale Versari 1

Abstract: Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option in patients with metastatic neuroendocrine tumor (NET). However, PRRT fails in about 15–30% of cases. Identification of biomarkers predicting the response to PRRT is essential for treatment tailoring. We aimed to evaluate the predictive and prognostic role of semiquantitative and volumetric parameters obtained from the 68Ga-DOTATOC PET/CT before therapy (iPET) and after two cycles of PRRT (iPET). A total of 46 patients were included in this retrospective analysis. The primary tumor was apparently does not provide information useful to change the management of NET patients. The aim of this study was to identify biomarkers derived from baseline and interim 68Ga-DOTATOC PET/CT in patients undergoing PRRT. In 46 metastatic NET patients with available baseline and interim PET, only baseline total tumor volume (bTV) was able to discriminate responders to PRRT (partial response or stable disease) vs. non-responders. Patients with high bTV had also the worst overall survival. bTV, an imaging biomarker, integrated in the initial workup of NET patients could improve risk stratification and contribute to a tailored therapy approach.

Keywords: neuroendocrine tumor; GEP-NET; PET/CT; PRRT; DOTATOC
1. Introduction

Neuroendocrine tumors (NETs) are relatively rare neoplasms that originate from endocrine cells, mostly of the gastroenteropancreatic tract (GEP) and the pulmonary system. Due to their indolent natural course, NETs are identified as locally advanced or with distant metastasis in 40–50% of patients [1].

Peptide receptor radionuclide therapy (PRRT) is an effective systemic therapeutic option for patients with advanced, metastatic, or unresectable NETs with high somatostatin receptor (SSTR) expression. PRRT consists in the intravenous systemic administration of somatostatin analogs (SSAs) labeled with a β-minus (β-) emitting radioisotope (90Y and 177Lu), that binds SSTRs overexpressed in tumors with high affinity and specificity. The compound is internalized by endocytosis and retained in lysosomes of cells allowing the delivery of cytotoxic radiation directly on target cells, therefore producing the breakdown of intracellular DNA chains and cell death [2]. Although a significant improvement has been reported in progression free survival (PFS) and overall survival (OS), disease progression is still observed in 20–30% of patients treated with PRRT [3]. Moreover, PRRT can be associated with hematologic, renal, and hepatic toxicities [4]. Therefore, the early identification of patients who are at high risk of treatment failure represents an unmet need.

Positron emission tomography/computed tomography with 68Ga-DOTA-labelled somatostatin analogues (68Ga-DOTA-peptide PET/CT) is the elective imaging technique for diagnosis and management of NETs [5]. In clinical practice PET/CT plays a pivotal role also for properly selecting patients as candidates for PRRT. 68Ga-DOTA-peptide PET imaging is used for both evaluation of somatostatin receptor expression and correct staging of disease [6].

In addition, PET derived parameters, such as the semiquantitative standardized uptake values (SUVs), have been widely studied as prognostic and predictive factors in NET patients treated with PRRT [7]. In several other malignancies, FDG-PET-derived metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which is the product of SUVmean × MTV, have shown a major role in prognosis and treatment monitoring compared to SUVs parameters [8]. MTV and TLG provide a direct estimation of the whole-body tumor burden and have been validated as quantitative imaging biomarkers in several tumors [9]. Furthermore, early changes in tumor burdens are a promising index of response to treatment and could be the basis of a more individualized treatment approach [10,11].

Hence, the aim of this study is to evaluate the predictive and prognostic value of semiquantitative and volumetric parameters calculated from 68Ga-DOTATOC PET/CT performed before PRRT. Moreover, we assessed the potential role of the change (Δ) between baseline and interim PET parameters after two cycles of PRRT for early prediction of response.

2. Materials and Methods
2.1. Study Design

We conducted a retrospective subgroup analysis of patients enrolled in a prospective, monocentric, non-randomized phase II clinical trial (EudraCT:2013-002605-65). All patients signed a written informed consent form. For this study we included biopsy-proven, unresectable, metastatic GEP or bronchopulmonary or unknown primary site NET patients, who were treated with PRRT in our institution (Azienda USL-IRCCS of Reggio Emilia, Italy). All patients underwent screening with 68Ga-DOTATOC PET/CT to confirm the adequate expression of SSTR type 2 on tumor sites and an interim PET/CT scan 7 weeks after the second cycle of PRRT. The association between PET parameters and outcomes (PRRT response and OS) was evaluated.

2.2. Ga-DOTATOC PET/CT

A baseline 68Ga-DOTATOC PET/CT (bPET) 1–3 weeks before PRRT and after two cycles of PRRT (interimPET) was performed with a hybrid scanner (Discovery STE; GE Healthcare). Image acquisition started 60 ± 10 min after administration of 2 MBq/kg of
68Ga-DOTATOC. All DOTATOC-avid lesions were semiautomatically segmented by an experienced board-certified nuclear medicine physician (V.C.) using a commercial software (PET VCAR, GE Healthcare). Subsequently, all regions of physiological or non-disease related uptake were manually removed. From the remaining volume-of interests (VOIs), containing all 68Ga-DOTATOC avid tumor lesions, maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), the somatostatin receptor-derived tumor volume (TV) and total lesion SSR expression (Total Lesion Activity-TLA, defined as SUVmean × TV) were measured. Based on the experience of metabolic tumor volume in FDG PET/CT studies a threshold above 41% of SUVmax was used to calculate TV. The whole-body tumor volume (bTV) was calculated by summing TV measurements of all lesions in each patient. The whole-body TLA (bTLA) was calculated by summing TLA of all lesions. Also, the ratio of the lesion SUVmax to the SUVmax in the spleen (SUVratio T/S) was calculated. Differences (Δ) in SUVmax, SUVmean, bTV, bTLA and SUVratio T/S were evaluated by calculating the percentage in variation of each parameter using the following formula: Delta = (interimPET − bPET)/bPET × 100.

2.3. PRRT

PRRT was performed according to the joint International Atomic Energy Agency (IAEA; Vienna, Austria), European Association of Nuclear Medicine (EANM; Vienna, Austria), and Society of Nuclear Medicine and Molecular Imaging (SNMMI; Reston, VA, USA) practical guidance ([12]). Briefly, the inclusion criteria for treatment with PRRT were histologically confirmed, unresectable, metastatic GEP or bronchopulmonary or unknown primary site NET patients; high expression of somatostatin receptor on baseline 68Ga-DOTATOC PET/CT (defined as greater than or equal to that of normal liver); a glomerular filtration rate greater than 50 mL/min/1.73 m²; a white blood cell count greater than 2.5 × 10⁹/L; a platelet count greater than 90 × 10⁹/L; bilirubin levels less than 2.5 mg/dL and ECOG performance status ≤ 2. A fractionated treatment protocol, with an activity of 1850–2590 MBq 90Y-DOTATOC or 3700–5550 MBq 177Lu-DOTATOC per treatment cycle every eight weeks, aimed at four to six courses with an interval of eight weeks, was followed. The activity prescription was determined on the basis of the Biological Effective Dose (BED) delivered to kidneys and on the basis of the absorbed dose to bone marrow, considered as the main organs at risk. Dosimetry was scheduled during the first course of therapy after a therapeutic administration of 177Lu-DOTATOC. The cumulative dose limit to kidneys was set to 46 Gy of BED for patients with no risk factors, and at 28 Gy for patients with risk factors, while the absorbed dose limit to bone marrow was set to 2 Gy for both. Documented disease progression at any time led to the cessation of PRRT and the classification of the patient as having progressive disease.

2.4. Assessment of Treatment Response

Response assessment was performed three months after completion of PRRT courses. Combination of anatomical imaging (CT/MRI), functional (PET) and clinical data in a multidisciplinary tumor board setting was used to define response. Response Evaluation criteria in Solid Tumors (RECIST version 1.1) criteria was used in determining anatomical response to PRRT. PET response was assessed using the European Organization for Research and Treatment of Cancer (EORTC) criteria. For the study analysis, responders were defined as patients with a complete/partial response or stable disease, and non-responders had progressive disease.

2.5. Statistical Analysis

Quantitative variables were expressed as median with range or mean with SD. Categorical variables are presented with absolute and relative frequencies. Mann-Whitney U test was used for comparing continuous variables between responders and non-responders. Chi-square test was used to analyze differences in discrete variables between responders and non-responders. Binary logistic regression was performed to identify factors predictive
of treatment. Receiver operating characteristics (ROC) analysis was performed to identify optimal cut-off values for PET/CT quantitative parameters. The area under the curves (AUC), sensitivity, specificity and accuracy were reported. Survival curves were estimated according to the Kaplan-Meier method. A log-rank test was used to compare survival curves. Cox proportional-hazards model was used for univariate and multivariate survival analysis and results were reported as hazard ratio (HR), 95% confidence interval (95%CI) and p-Value based on statistical Wald-test. OS was defined as the time (months) from the first PRRT cycle to death from any cause. Surviving patients were censored at the last date of follow-up. All statistical tests were two-sided and p < 0.05 was considered a statistically significant result. Statistical analysis was performed using IBM SPSS Statistics 25 (IBM, New York, NY, USA) and MedCalc Statistical Software 14.8.1 (Ostend, Belgium) for Windows.

3. Results

3.1. Patients

A total of 46 patients with available bPET and iPET were included in this retrospective analysis. The median age was 60 (range 25–85) and 21 patients (46%) were female. Primary tumor was for 78% GEP, 13% broncho-pulmonary and 9% of unknown origin. All patients had stage IV disease. Liver and lymph nodes were the most frequent sites of metastasis. Patients’ main characteristics are reported in Table 1.

Table 1. Main characteristics of the study population.

| Patients | (n = 46) |
|----------|---------|
| Age, median (range) in years | 60 (25–85) |
| Gender, n (%) | |
| Male | 25 (54%) |
| Female | 21 (46%) |
| Primary tumour, n (%) | |
| GEP | 36 (78%) |
| Stomach | 3 (8%) |
| Pancreas | 8 (22%) |
| Intestine | 25 (70%) |
| Broncho-Pulmonary | 6 (13%) |
| Unknown | 4 (9%) |
| GEP NETs WHO grade, n (%) | |
| G1 ((Ki-67 0–2%)) | 21 (46%) |
| G2 (Ki-67 3–20%) | 19 (41%) |
| G3 (Ki-67 >20%) | 2 (4%) |
| NA | 4 (9%) |
| Metastasis, n | |
| Liver | 21 |
| Lymph nodes | 23 |
| Bone | 15 |
| Lung | 7 |
| Other | 9 |
| Cycles of PRRT, n (%) | |
| 2 | 2 (4%) |
| 3 | 1 (2%) |
| 4 | 5 (11%) |
| 5 | 11 (24%) |
| 6 | 27 (59%) |
| Type of PRRT | |
| Only 177Lu | 5 (11%) |
| 177Lu + 90Y | 41 (89%) |

Abbreviations: GEP: gastroenteropancreatic; PRRT: peptide receptor radionuclide therapy; NET: neuroendocrine tumor.
3.2. PRRT and PET/CT

Forty-three patients (94%) received four to six cycles of PRRT. Five patients (11%) were treated with 177Lu-DOTATOC radiopeptide, while the 41 remaining subjects underwent a combination of 90Y-DOTATOC and 177Lu-DOTATOC therapy.

The observed response rates were 21% \((n = 10)\) partial response, 55.1% \((n = 25)\) stable disease, and 23.9% \((n = 11)\) progressive disease for the entire cohort. Considering GEP NET cohort response rates were 27% \((n = 10)\) partial response, 51% \((n = 18)\) stable disease, and 22% \((n = 8)\) progressive disease. Complete response was not observed. For the analysis of this study, 35 patients (76.1%) with either stable disease or partial response after PRRT were classified as responders and 11 (23.9%) patients with progressive disease as non-responders.

The median values of SUV\(_{\text{max}}\), SUV\(_{\text{mean}}\), SUV\(_{t/s}\), bTV, and bTLA were 34 (IQR, 23.1–55.8), 9.9 (IQR, 7.6–16.4), 1.1 (IQR, 0.7–2.3), 143.8 mL (IQR, 32.9–354), and 1834 (IQR, 342–6309), respectively. The median percentage in variation between baseline and interim PET after two cycles of PRRT reported as \(\Delta\)SUV\(_{\text{max}}\), \(\Delta\)SUV\(_{\text{mean}}\), \(\Delta\)SUV\(_{t/s}\), \(\Delta\)bTV, \(\Delta\)bTLA were 1.1% (IQR, −21.2–22.1), 4.2% (IQR, −17.8–39.4), −1.1% (IQR, −41.5–24.5), 32.4% (IQR, −10.2–70.6), 25% (−12.5–80.9), respectively. Figure 1 shows a baseline and interim PET.

![Baseline (A) and interim (B) PET scan of a 54-year-old patient with G1 pancreatic NET. Red arrows indicate the primary pancreatic tumor and the most representative liver metastasis. Interim 68Ga-DOTATOC PET after the second PRRT cycle shows disease progression. The patient was treated with a total of six PRRT courses (four cycles of 177Lu-DOTATOC + 2 cycles of 90Y-DOTATOC) for a total of 28,534 MBq activity and classified as partial response at the assessment following treatment.](image)

The bTV and bTLA values of patients that did not respond to PRRT were significantly higher than those of patients with response to PRRT therapy (496.2 IQR 218.3–2029.4 vs. 77.6 IQR 31–186.6, \(p < 0.001\) and 6078.3 IQR 2813–18,959 vs. 1341 IQR 272.3–3865, \(p = 0.001\), respectively: Figure 2).
Figure 1. Baseline (A) and interim (B) PET scan of a 54-year-old patient with G1 pancreatic NET. Red arrows indicate the primary pancreatic tumor and the most representative liver metastasis. In-terim 68Ga-DOTATOC PET after the second PRRT cycle shows disease progression. The patient was treated with a total of six PRRT courses (four cycles of 177Lu-DOTATOC + 2 cycles of 90Y-DOTATOC) for a total of 28,534 MBq activity and classified as partial response at the assessment following treatment.

The bTV and bTLA values of patients that did not respond to PRRT were significantly higher than those of patients with response to PRRT therapy (496.2 IQR 218.3–2029.4 vs. 77.6 IQR 31–186.6, p < 0.001 and 6078.3 IQR 2813–18,959 vs. 1341 IQR 272.3–3865, p = 0.001, respectively: Figure 2).

Figure 2. Box Plot comparing bTV (a) and bTLA (b) between PRRT responder and non-responder patients. “★” and “○” symbols represent outlier cases.

No association between semiquantitative PET parameters and response were observed. Percentage variations (Δ) of PET semiquantitative and volumetric parameters were not significantly different between PRRT responders and non-responders. PET parameters and comparison between responders vs. non-responders are summarized in Table 2.

Table 2. Characteristic of calculated PET parameters. Data of all patients (n = 46) and a comparison between responders (n = 35) vs. non-responders (n = 11) groups are reported. Values are expressed in mean (SD) and median (IQR). Mann-Whitney U test was used to compare variables. The p-Values shown in boldface correspond to p < 0.05.
Table 2. Cont.

| PET Parameters | All \((n = 46)\) | Responders \((n = 35)\) | Non-Responders \((n = 11)\) | \(p\) Value |
|----------------|-----------------|------------------------|------------------------|------------|
| \(\Delta TV\)  | Mean (SD)       | 61 (170)               | 27.1 (55.6)            | 71.5 (756.7)| 0.51       |
|                | Median (IQR)    | 32.4 (−10.2–70.6)      | 32.4 (−5.5–69.2)       | 32.4 (−23.9–79.9)|            |
| \(\Delta TLA\) | Mean (SD)       | 143 (668.4)            | 45.7 (79.1)            | 171.9 (756.7)| 0.92       |
|                | Median (IQR)    | 25 (−12.5–80.9)        | 24.3 (−0.4–80)         | 36 (−22.5–111)|            |

Abbreviations: SUV: standardized uptake value; T/S: tumor/spleen; TV: total volume; TLA: total lesion activity.

Logistic regression analysis of bPET derived parameters and \(\Delta PET\) values identified that only bTV was associated with therapy outcome (OR 1.17; 95%CI 1.02–1.32; \(p\) = 0.02). No significant association with PRRT response was observed for other variables (Table 3).

Table 3. Logistic Regression Analysis.

| PET Parameters | Univariate Analysis | \(p\) Value |
|----------------|---------------------|------------|
|                | OR (95%CI)          |            |
| SUVmax         | 1.06 (0.99–1.13)    | 0.09       |
| SUVmean        | 0.8 (0.55–1.15)     | 0.23       |
| SUVratio T/S   | 0.84 (0.52–1.35)    | 0.48       |
| bTV            | 1.17 (1.02–1.32)    | 0.02       |
| bTLA           | 0.99 (0.93–1.01)    | 0.08       |
| \(\Delta SUV\)max | 0.97 (0.93–1.01)    | 0.25       |
| \(\Delta SUV\)mean | 1.007 (0.98–1.01)   | 0.259      |
| \(\Delta SUV\)ratio T/S | 0.99 (0.98–1.01)    | 0.839      |
| \(\Delta TV\)  | 0.99 (0.98–1.01)    | 0.922      |
| \(\Delta TLA\) | 0.99 (0.98–1.01)    | 0.70       |

Abbreviations: SUV: standardized uptake value; T/S: tumor/spleen; TV: total volume; TLA: total lesion activity. The \(p\)-Values shown in boldface correspond to \(p < 0.05\).

3.3. Overall Survival Analysis

During the follow-up period (mean 31 months; ranged from eight to 86 months), seven (15.2%) patients died. Mean survival time was 69.4 (SD, 5.3) months, the median was non reached for the entire cohort.

ROC analysis showed a best cut-off point for bTV of >244.5 mL (sensitivity 85.7%; specificity 79.5%) and AUC of 0.77 (95% CI 0.62–0.88, \(p\) = 0.036) for identification of patients with worse OS. For bTLA best cut-off point was 2659 (sensitivity 85.7%; specificity 64.1%) and AUC of 0.71 (95% CI 0.56–0.84, \(p\) = 0.092). The complete ROC curves analysis of PET parameters is shown in Table S1.

In univariate analysis, higher bTV and bTLA were associated with lower survival probability (HR 13 95%CI 2.6–64.1, \(p\) = 0.001; HR 9.08 95%CI 1.09–75.76, \(p\) = 0.04) (Figure 3).

Moreover, a difference in SUVmax above 5.5% between iPET and bPET (\(\Delta SUV\)max) was associated with a favourable outcome (HR 0.15 95% CI0.03–0.67; \(p\) = 0.04). In Cox multivariate analysis, only a high bTV was confirmed as an independent prognostic factor (HR 12.76 95%CI 1.53–107, \(p\) = 0.01) (Table 4).
Abbreviations: SUV: standardized uptake value; T/S: tumor/spleen; TV: total volume; TLA: total lesion activity.

Univariate and multivariate Cox regression analysis for OS.

The phase III NETTER-1 trial has established that PRRT prolongs GEP-NETs with progressive disease by the European Medicine Agency in 2017, PRRT has been widely used [13,14]. During about 20 years of retrospective and phase I/II trials, PRRT was finally approved a complete identification was achieved in the best predicted bTV (2658 mL*SUV) in the ROC curve (2658 mL*SUV).

| PET Parameter | Univariate Analysis | Multivariate Analysis |
|---------------|---------------------|----------------------|
|               | HR (95% CI)         | p Value              | HR (95% CI) | p Value |
| SUVmax (>22.02) | 0.99 (0.12–8.20) | 0.99 | - | - |
| SUVmean (≤5.45) | 0.31 (0.06–1.51) | 0.26 | - | - |
| SUVratioT/S (≤1.31) | 0.84 (0.08–8.23) | 0.87 | - | - |
| bTV (>244.48) | 13 (2.6–64.1) | 0.001 | 12.76 (1.53–107) | 0.01 |
| bTLA (>2658.62) | 9.08 (1.09–75.76) | 0.04 | 7.15 (0.96–68.1) | 0.98 |
| ∆SUVmax (>5.5598) | 0.15 (0.03–0.67) | 0.04 | 0.17 (0.02–1.46) | 0.1 |
| ∆SUVmean (>24.4984) | 0.65 (0.05–7.87) | 0.68 | - | - |
| ∆SUVratioT/S (>–0.75) | 0.14 (0.017–1.28) | 0.08 | - | - |
| ∆TV (≤–15.876) | 0.23 (0.02–1.86) | 0.354 | - | - |
| ΔTLA (>80.2) | 0.45 (0.082–2.48) | 0.2737 | - | - |

The p-Values shown in boldface correspond to p < 0.05.

4. Discussion

After about 20 years of retrospective and phase I/II trials, PRRT was finally approved by regulatory authorities. Since its approval for the treatment of inoperable or metastatic GEP-NETs with progressive disease by the European Medicine Agency in 2017, PRRT has been widely used [13,14]. The phase III NETTER-1 trial has established that PRRT prolongs...
PFS compared to high dose octreotide LAR and improved quality of life. [3,15] In our study, 76.1% of NET patients had stable disease or partial response and 23.9% patients showed progressive disease after PRRT. These findings are in line with the response rates reported in a recent large meta-analysis where the disease control rate (complete or partial response and stable disease) was 83% in metastatic NET patients treated with PRRT [16]. Despite the increasing role of PRRT in metastatic NETs, what is clear both from our results and literature is that we need parameters to improve the selection of patient candidates to PRRT.

In this study, we evaluated the predictive and prognostic significance of semiquantitative and volumetric baseline PET imaging parameters in patients with advanced, metastatic NET undergoing PRRT. We also investigated the role of interim PET after two cycles of PRRT as an early predictor.

Several retrospective studies have assessed the role of semiquantitative parameters, mostly SUVmax, as prognostic markers for NETs. However, conflicting results have been published regarding the role of SUV on baseline 68Ga-DOTA-SSA PET in PRRT response prediction. Several authors demonstrated that a high SUVmax in baseline PET is associated with a favorable outcome and a wide range of different cut-off values are reported to separate responders to PRRT vs. non responders [17–20].

In our cohort we did not find any association between SUVs obtained in the baseline PET and PRRT response. This finding is in line with published results by Gabriel et al. and Soydal et al., who similarly found that SUVs showed no additional value for PRRT response prediction [21,22]. This controversial result may be because SUVs are measured in a single region of interest and thus they are not representative of the total tumor burden. Indeed, the lesion heterogeneity in NET patients, and the well-known limits of semiquantitative parameters, might further limit SUVs utility [23].

We found that patients who did not respond to PRRT had significantly higher bTV compared to responders. Moreover, bTV was the only PET parameter that confirmed a predictive role for PRRT response on logistic regression analysis (OR 1.17). Furthermore, bTV was an independent prognostic factor associated with worse OS rates in Cox regression analysis.

To our knowledge, only two other studies have previously evaluated the role of baseline volumetric PET parameters in patients treated with PRRT. Ohlendorf et al. found that PFS was shorter in patients with high bTV and high bTLA in 32 NET patients treated with PRRT [22]. Pauwels et al. reported that a bTV higher than 578 mL was associated with worse OS [23]. In our study population, the bTV cut-off that better identified patients with shorter OS was 244 mL. This difference in cut-offs could be explained by different segmentation methods. Indeed, Pauwels used a SUV threshold customized per patient through visual inspection to segment the tumor. In contrast, we used a semiautomatic method applying a threshold above 41% of the SUVmax for calculation of TV and TLA, based on the experience with FDG PET studies [24]. Further studies are warranted to define and harmonize 68Ga-Dota-peptide PET/CT tumor burden segmentation.

Our findings are in line with several previous studies that assessed the prognostic significance of PET volumetric parameters in settings other than PRRT [25–30]. Thus, bTV seems to be a powerful prognostic parameter in NET patients. However, bTV should be validated in further prospective studies including more homogeneous populations in terms of primary site, disease course and treatment setting.

In contrast, we did not find any relationship between changes in PET semiquantitative and volumetric parameters between baseline and interim PET after two cycles of PRRT. However, changes in SUVmax (ΔSUVmax) showed a significance in OS univariate analysis (p = 0.04) that was not confirmed in multivariate analysis. These results, in accordance with previous studies, show no utility of iPET in guiding the management of metastatic NET patients treated with PRRT [11,27].

There are several limitations of the present study that should be acknowledged. First are the retrospective nature and the small sample size. Second, we included patients
with different NET sites. Furthermore, we did not evaluate FDG PET findings in our analysis. It is known that some patients with grade 2–3 NET can show higher affinity for FDG rather than 68Ga-DOTATOC PET [28]. This can result in an underestimation of the actual tumor burden by 68Ga-DOTATOC PET. A combination of these two tracers can be considered to address this issue. In addition, it should be noted that the generalizability of our findings with 68Ga-DOTATOC to the other often used 68Ga-DOTATATE PET ligand need to be confirmed. Indeed, while 68Ga-DOTATATE shows only affinity to SSTR2, 68Ga-DOTATOC also exhibits some affinity to SSTR5. However, despite differences in receptor affinities, a head-to-head comparison showed no clinically significant difference between the two tracers [29]. Finally, it is worth mentioning that other PET tracers like 64Cu-DOTATATE, providing better resolution and potentially a better lesion detection rate than 68Ga-DOTATOC, may improve tumor burden quantification [30]. However, the 64Cu-labeled tracers are not in use in the clinical routine and require further work.

5. Conclusions

In metastatic NET patients addressed to PRRT, higher total body tumor volume measured from baseline 68Ga-DOTATOC PET/CT scans is a negative predictor for therapy response and is associated with worse OS rates. Interim 68Ga-DOTATOC PET/CT after two cycles of PRRT did not allow the identification of patients with poorer prognosis that would justify a change in treatment strategy.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers14030592/s1, Table S1: ROC curve analysis for OS.

Author Contributions: Conceptualization and supervision A.V. and A.F. (Angelina Filice); data acquisitions, V.C. and C.C.; data analysis, F.F. and D.F.; writing—original draft preparation, R.D.; revision of the article for important intellectual content, A.F. (Andrea Frasoldati), S.F. and G.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of AUSL-IRCCS of Reggio Emilia (protocol code 24871).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy-related issues.

Conflicts of Interest: A.V.: Novartis and Advanced Accelerator Applications for advisory role. The other authors declare no conflict of interest.

References

1. Dasari, A.; Shen, C.; Halperin, D.; Zhao, B.; Zhou, S.; Xu, Y.; Shih, T.; Yao, J.C. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017, 3, 1335–1342. [CrossRef]
2. Eychenne, R.; Bouvry, C.; Bourgeois, M.; Loyer, P.; Benoist, E.; Lepareur, N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020, 25, 4012. [CrossRef] [PubMed]
3. Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 125–135. [CrossRef] [PubMed]
4. Bodei, L.; Kidd, M.; Paganelli, G.; Grana, C.M.; Drozdov, I.; Cremonesi, M.; Lepensky, C.; Kwekkeboom, D.J.; Baum, R.P.; Krenning, E.P.; et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 5–19. [CrossRef] [PubMed]
5. Shah, M.H.; Goldner, W.S.; Halfdanarson, T.R.; Bergsland, E.; Berlin, J.D.; Halperin, D.; Chan, J.; Kulke, M.H.; Benson, A.B.; Blaszkowsky, L.S.; et al. Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines. JNCNN J. Natl. Compr. Cancer Netw. 2018, 16, 693–702. [CrossRef] [PubMed]
6. Filice, A.; Fraternali, A.; Frasoldati, A.; Asti, M.; Grassi, E.; Massi, L.; Sollini, M.; Froio, A.; Erba, P.A.; Versari, A. Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience. J. Oncol. 2012, 2012, 320198. [CrossRef] [PubMed]
Albertelli, M.; Dotto, A.; Di Dato, C.; Malandrino, P.; Modica, R.; Versari, A.; Colao, A.; Ferone, D.; Faggiano, A. PRRT: Identikit of the perfect patient. *Rev. Endocr. Metab. Disord.* 2021, 22, 563–579. [CrossRef] [PubMed]

Cottereau, A.S.; Versari, A.; Loft, A.; Casasnovas, O.; Bellei, M.; Ricci, R.; Bardet, S.; Castagnoli, A.; Brice, P.; Raemaekers, J.; et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. *Blood* 2018, 131, 1456–1463. [CrossRef] [PubMed]

Hofheinz, F.; Li, Y.; Steffen, I.G.; Lin, Q.; Lili, C.; Hua, W.; van den Hoff, J.; Zscheack, S. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 1485–1494. [CrossRef] [PubMed]

Ohlendorf, F.; Werner, R.A.; Henkenberens, C.; Ross, T.L.; Christiansen, H.; Bengel, F.M.; Derlin, T. Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy. *Diagnoses* 2021, 11, 504. [CrossRef] [PubMed]

Ortega, C.; Wong, R.K.S.; Schaferkoetter, J.; Veit-Haibach, P.; Myrehaug, S.; Juergens, R.; Laidley, D.; Anconina, R.; Liu, A.; Mesters, U. Quantitative 68 Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177 Lu-DOTATATE. *J. Nucl. Med.* 2021, 62, 1406–1414. [CrossRef] [PubMed]

Zaknun, J.J.; Bodei, L.; Mueller-Brand, J.; Pavel, M.E.; Baum, R.P.; Hörsch, D.; O’Dorisio, M.S.; O’Dorisio, T.M.; Howe, J.R.; Cremonesi, M.; et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. *Eur. J. Nucl. Med. Mol. Imaging* 2013, 40, 800–816. [CrossRef] [PubMed]

CHMP Lutathera, INN-Lutetium (177Lu) Oxodotreotide. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf (accessed on 23 January 2022).

Cives, M.; Strosberg, J. Radionuclide Therapy for Neuroendocrine Tumors. *Curr. Oncol. Rep.* 2017, 19, 1–9. [CrossRef] [PubMed]

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Kunz, P.; Hobday, T.; Hendi, S.; et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177 lu-dotatate in the phase III netter-1 trial. *J. Clin. Oncol.* 2018, 36, 2578–2584. [CrossRef] [PubMed]

Wang, L.; Lin, L.; Wang, M.; Li, Y. The therapeutic efficacy of 177lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors. *Medicine* 2020, 99, e19304. [CrossRef] [PubMed]

Öksüz, M.Ö.; Winter, L.; Pfannenberg, C.; Reischl, G.; Müssig, K.; Bares, R.; Dittmann, H. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATATE: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? *Diagn. Interv. Imaging* 2014, 95, 289–300. [CrossRef] [PubMed]

Kratochwil, C.; Stefanova, M.; Mavriopoulou, E.; Holland-Letz, T.; Dimitrakopoulou-Strauss, A.; Afshar-Oromieh, A.; Mier, W.; Haberkorn, U.; Giesel, F.L. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. *Mol. Imaging Biol.* 2014, 17, 313–318. [CrossRef] [PubMed]

Gabriel, M.; Oberauer, A.; Dobrozensky, G.; Decristoforo, C.; Putzer, D.; Kendler, D.; Uprimny, C.; Kovacs, P.; Bale, R.; Virgolini, I. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. *J. Nucl. Med.* 2009, 50, 1427–1434. [CrossRef] [PubMed]

Soydul, Ç.; Peker, A.; Özkan, E.; Küçük, Ö.N.; Kir, M.K. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with lu-177 DOTATATE. *Turk. J. Med. Sci.* 2016, 46, 409–413. [CrossRef]

Werner, R.A.; Ilhan, H.; Lehner, S.; Papp, L.; Zsöötér, N.; Schatka, I.; Muegge, D.O.; Javadi, M.S.; Higuchi, T.; Buck, A.K.; et al. Pre-therapy Somatostatin Receptor-Based Radiobiology Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. *Mol. Imaging Biol.* 2019, 21, 582–590. [CrossRef] [PubMed]

Ohlendorf, F.; Henkenberens, C.; Brunkhorst, T.; Ross, T.L.; Christiansen, H.; Bengel, F.M.; Derlin, T. Volumetric 68Ga-DOTATE/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. *Q. J. Nucl. Med. Mol. Imaging* 2020. [CrossRef] [PubMed]

Pauwels, E.; Van Binnebeek, S.; Vandecaveye, V.; Baete, K.; Vanbilloen, H.; Koole, M.; Mottaghy, F.M.; Haustermans, K.; Clement, P.M.; Nackaerts, K.; et al. Inflammation-based index and 68ga-dotatoc pet-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90y-dotatoc. *J. Nucl. Med.* 2020, 61, 1014–1020. [CrossRef] [PubMed]

Meignan, M.; Sasaneli, M.; Casasnovas, R.O.; Luminari, S.; Fioroni, F.; Coriani, C.; Masset, H.; Itti, E.; Gobbi, P.G.; Merli, F.; et al. Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients. *Eur. J. Nucl. Med. Mol. Imaging* 2014, 41, 1113–1122. [CrossRef] [PubMed]

Tirosh, A.; Papadakis, G.Z.; Millo, C.; Hammoud, D.; Sadowski, S.M.; Herscovitch, P.; Pacak, K.; Marx, S.J.; Yang, L.; Nockel, P.; et al. Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors. *Gastroenterology* 2018, 154, 998–1008.e1. [CrossRef] [PubMed]

Abdulrezzak, U.; Kurt, Y.K.; Kula, M.; Tutus, A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. *Nucl. Med. Commun.* 2016, 37, 874–881. [CrossRef] [PubMed]

Haug, A.R.; Auernhammer, C.J.; Wängler, B.; Schmidt, G.P.; Uebelies, C.; Göke, B.; Cumming, P.; Bartenstein, P.; Tiling, R.; Hacker, M. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. *J. Nucl. Med.* 2010, 51, 1349–1356. [CrossRef] [PubMed]
28. Binderup, T.; Knigge, U.; Johnbeck, C.B.; Loft, A.; Berthelsen, A.K.; Oturai, P.; Mortensen, J.; Federspiel, B.; Langer, S.W.; Kjaer, A. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. *J. Nucl. Med.* 2021, 62, 808–815. [CrossRef] [PubMed]

29. Poeppel, T.D.; Birse, I.; Petersenn, S.; Lahner, H.; Schott, M.; Antoch, G.; Brandau, W.; Bockisch, A.; Boy, C. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. *J. Nucl. Med.* 2011, 52, 1864–1870. [CrossRef] [PubMed]

30. Johnbeck, C.B.; Knigge, U.; Loft, A.; Berthelsen, A.K.; Mortensen, J.; Oturai, P.; Langer, S.W.; Elema, D.R.; Kjaer, A. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. *J. Nucl. Med.* 2017, 58, 451–457. [CrossRef] [PubMed]